Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models

Autor: Cope, Shannon, Ouwens, Mario J.N.M., Jansen, Jeroen P. , Schmid, Peter
Zdroj: In Value in Health March-April 2013 16(2):403-417
Databáze: ScienceDirect